Eficácia e segurança da toxina botulínica no tratamento da paraparesia espástica: revisão sistemática / Efficacy and safety of botulinum toxin in the treatment of spastic paraparesis: systematic review

A paraparesia espástica é caracterizada pela perda de função total ou parcial dos membros inferiores associado ao aumento do tônus muscular velocidade-dependente. A toxina botulínica é utilizada no tratamento de diversos padrões de espasticidade, sejam em flexão, extensão ou adução. Objetivo: determinar a eficácia e segurança do bloqueio químico com toxina botulínica em pacientes com paraparesia espástica. Método: foi realizada uma revisão sistemática com busca nas bases de dados do PUBMED, MEDLINE, LILACS e SCIELO. Os critérios de inclusão foram: ensaios clínicos que utilizaram a toxina botulínica para o tratamento de pacientes com paraparesia espástica e publicados em inglês a partir da década de 1980. Os desfechos considerados foram: a pontuação na Escala de Ashworth Modificada, a amplitude de movimento passiva e ativa e os efeitos adversos da toxina botulínica. Resultados: foram incluídos cinco artigos. Todos mostraram melhora da espasticidade nos pacientes estudados. Quatro artigos mostraram aumento da amplitude de movimento passivo e três relataram aumento da amplitude de movimento ativo. Três artigos trouxeram relatos de efeitos adversos após o uso da toxina botulínica, mas a maioria deles não eram graves e cessaram espontaneamente. Conclusão: os estudos analisados mostraram que a toxina botulínica é eficaz e segura em pacientes com paraparesia espástica.(AU)

Spastic paraparesis is the loss of total or partial lower limb function associated with increased speed-dependent muscle tone. Botulinum toxin is used in the treatment of several spasticity presentations that include flexion, extension and adduction. Objective: To determine both safety and efficacy of botulinum toxin as a blocking agent in the treatment of spastic paraparesis. Method:A systematic review was carried out with a search on PUBMED, MEDLINE, LILACS and SCIELO databases. The inclusion criteria were: clinical trials that used botulinum toxin for the treatment of patients with spastic paraparesis and published in English from the 1980s. The following outcomes were assessed by the studies: the Ashworth Modified scale score, the range of passive and active motion and botulinum toxin adverse effects. Results:Five articles were included. All of them showed spasticity improvements in the patients. Four studies showed increases in passive range of motion and three articles showed increase in active range of motion. Three papers reported adverse effects after botulinum toxin use but they were mostly mild and ceased spontaneously. Conclusion: Most analyzed studies indicated that botulinum toxin is safe and efficient inthe treatment of spastic paraparesis. (AU)

Two Babinski signs in seropositive (HAM) and seronegative tropical spastic paraparesis / Dos signos de Babinski en pacientes con paraparesia espástica tropical seropositiva (HAM) y seronegativa

Tropical spastic paraparesis (TSP) may or may not be associated to HTLV-I antibodies and is usually characterized by clinical and pathological spinal cord abnormalities at thoracic levels. We present here five Brazilian patients who had typical chronic idiopatic spastic paraparesis; two of them were HTLV-I seropositive (HAM) and three HTLV-I seronegative (TSP) - associated-myelopathy. Three out of these five patients also displayed clinical supraspinal involvement, indeed, platysma muscle hypotrophy or atrophy (the Babinski plus sign). These findings support the view that clinical involvement in HAM and TSP is wider than the spinal cord abnormalities usually considered. Possible non-infectious co-factors (e.g., mycotoxins) may be involved in disease pathogenesis in a multistep process of viruses, toxins and environment which may account for serological differences found in this group of patients.

La paraparesia espástica tropical (PET), puede o no estar asociada con anticuerpos contra el HTLV-I y se caracteriza, usualmente, por alteraciones clínicas y patológicas a nivel de region dorso-lumbar de la medula espinal. Presentamos cinco pacientes brasileros, quienes tuvieron hallazgos típicos de paraparesia espástica crónica idiopática; dos de ellos tuvieron (HAM) y tres no tuvieron (TSP) anticuerpos, en el suero, contra el HTLV-I. En tres pacientes se encontró hipotrofia o atrofia del músculo platisma (signo de Babinski plus), demostrando que el compromiso clínico en pacientes con HAM y TSP se extiende más allá de la médula espinal torácica. Cofactores (por ejemplo, micotoxinas) podrían estar involucrados en la patogénesis de esta enfermedad, en una interacción compleja de virus, toxinas y medio ambiente, lo cual explicaría las diferencias serológicas encontradas en este grupo de pacientes.

Basilar impression associated with impacted cisterna magna, spastic paraparesis and distress of balance: case report / Impressão basilar associada com cisterna magna impactada, paraparesia espástica e distúrbios do equilíbrio: relato de caso

We report on a 48 years-old man with basilar impression without syringohydromyelia, in which the cisterna magna was impacted by the cerebellar tonsils. Six months after posterior fossa decompression there was the disappearance of nuchal rigidity, vertigo, spastic paraparesis and improvement of balance. Nevertheless hyperreflexia and diminished pallesthesia of the lower limbs persisted.

O presente relato descreve um homem de 48 anos com impressão basilar, sem siringo-hidromielia, no qual a cisterna magna se achava impactada pelas tonsilas cerebelares. O quadro clínico era caracterizado, especialmente, por paraparesia espástica. Seis meses após a descompressão da fossa posterior houve regressão da rigidez de nuca, vertigem, paraparesia espástica inicialmente observadas e melhora do equilíbrio. A hiperreflexia e a hipopalestesia persistiram nos membros inferiores.

Impacted cisterna magna without syringomyelia associated with spastic paraparesis: case report / Cisterna magna impactada sem siringomielia associada com paraparesia espástica: relato de caso

We report on a 49 year old man with impacted cisterna magna without the presence of syringohydromyelie (SM). The clinical picture was characterized by spastic paraparesis. Magnetic resonance imaging depicted a cisterna magna filled by the cerebellar tonsils. Six months after osteodural-neural decompression of the posterior fossa there was resolution of neurological symptoms and signs with the exception of hyperactive patellar and Achilles reflexes.

Hans Chiari (1891, 1895) descreveu 4 tipos de anomalias cerebelares que, ulteriormente, foram denominadas de malformação de Chiari (MC). Iskandar et al. (1998) relataram 5 casos de hidrosiringomielia (SM) sem herniação rombencefálica, nos quais as tonsilas cerebelares preenchiam a cisterna magna. Todos os casos melhoraram após a descompressão da fossa posterior com redução do tamanho da cavidade siringomiélica. Relatamos o caso de paciente de 49 anos com cisterna magna impactada sem a presença de siringo-hidromielia (SM). O quadro clínico caracterizava-se por paraparesia espástica. A ressonância magnética evidenciou a cisterna magna preenchida pelas tonsilas cerebelares. Seis meses após a descompressão osteodural-neural da fossa posterior, houve resolução dos sintomas e sinais neurológicos, com exceção da hiperatividade dos reflexos patelares e aquileus.

Paraparesia espástica tropical: a propósito de un caso clínico / Tropical spastic paraparesis: report of a case

Se presenta el caso clínico de una paciente con diagnóstico inicial de hipotiroidismo, cuadro que ameritó internación, compensado adecuadamente con levotiroxina. A pesar de existir buena respuesta al tratamiento instaurado, persiste la presencia de sintomatología de compromiso neurológico por lo que se solicita evaluación por dicha especialidad; se encuentran datos sugestivos de un cuadro de paraparesia espástica tropical, enfermedad producida por el HTVLI. El diagnóstico es confirmado mediante examenes de laboratorio. Es tratada con pentoxifilina y vitamina C con respuesta clínica inicial buena, pero posteriormente presenta exacerbación de las manifestaciones neurológicas, como sucede habitualmente en esta patología. nuestro país se encuentra en una regíon endemica de la infección mencionada, y sin embargo el diagnóstico es mas bien esporádico. Se discute en este artículo la epidemiología, las dificultades diagnósticas que planteo este caso en particular y las posibilidades terapéuticas de esta enfermedad neurológica.

We present the case of a female patient who initially was diagnosed with hypothyroidism, and adequately compensated with levotiroxin . In spite of the otherwise successfultreatment, neurological symptoms persisted. The neurological examination showed datasuggestive of tropical spastic paraparesis,a disease caused by HTVL-1.The diagnosis was confirmed by laboratory tests. The patient was treated with pentoxifiline and vitamin C, initially with a good clinical response. Later on, however, exacerbation of the neurological symptoms resulted, as usually happens in this disease. In our country, tropical spastic paraparesis is endemic but only sporadically diagnosed. We review the most relevant aspects of epidemiology, the diagnostic difficulty in this case, and the therapeutic options for this neurological disease.

Paraparesia espástica progresiva idiopática HTLV-I seronegativa: estudio clínico y neurofisiológico de las manifestaciones sensitivas / HTLV-I seronegative idiopathic progressive spastic paraparesis: clinical and neurophysiological study of the sensory features

Background: HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a defined entity. However, there are many patients not well characterized with a similar clinical picture who are HTLV-I seronegative. Objective: Clinical and neurophysiological description of patients with HTLV-I seronegative idiopathic paraparesia. Patients and Methods: Seventeen patients (4 women and 13 men aged 24-67 years, average 52.3) were evaluated including clinical assessment, vibratory sensory analysis, quantitative somatosensory thermotest (QST), somatosensory evoked potentials (SSEPs), electromyography (EMG) and motor and sensory nerve conductions. Results: In addition to the spastic paraparesis, 3 (17.6 percent) patients had pseudobulbar symptoms. Ten (58.8 percent) patients had a spastic gait but could walk unaided, 6 (35.2 percent) needed support and 1 patient could not walk. Bladder dysfunction was found in 10 (58.8) patients and sensory symptoms in 7 (41.1 percent). There was mild distal impairment of vibration and position sense, distal tactile and pinprick hypoesthesia in 4 (23.4 percent) patients. Tibial SSEPs were abnormal in 11 (64.7 percent). Nerve conduction studies and EMG were normal. QST showed cold hypoesthesia in 14 (82.4 percent) patients. Warm sensation and heat pain appeared unimpaired. Conclusions: All sensory abnormalities found were restricted to sensations carried by myelinated (A beta and A delta) channels. Sensory and motor abnormalities are similar to HAM/TSP patients suggesting a common pathogenesis

Intramedullary cysticercosis : MRI diagnosis.

Three cases of dorsal intramedullary cysticercosis presenting as spastic paraparesis or paraplegia are reported. A definite preoperative diagnosis, using MRI, was made in two cases while in the third it was strongly suspected. One paraplegic patient regained full function whereas in the other two the deficit persisted even after successful cyst excision. The pathogenesis and recovery are discussed in the light of the MRI findings.